Figure 1. Kaplan-Meier analysis of overall survival (OS) in patient subgroups stratified by (a) Hb level, (b) platelet-to-lymphocyte ratio (PLR) and (c) number of factors. (d) Receiver operating characteristic (ROC) curve analysis of PLR in 75 patients based on objective response rate (ORR) to pembrolizumab.